

General Announcement::Trendlines January 2016 Update

Issuer & Securities

Issuer/ Manager	THE TRENDLINES GROUP LTD.
Securities	THE TRENDLINES GROUP LTD. - IL0011328858 - 42T
Stapled Security	No

Announcement Details

Announcement Title	General Announcement
Date & Time of Broadcast	01-Feb-2016 07:02:18
Status	New
Announcement Sub Title	Trendlines January 2016 Update
Announcement Reference	SG160201OTHRJB1P
Submitted By (Co./ Ind. Name)	Yosef Ron
Designation	Joint Company Secretary
Description (Please provide a detailed description of the event in the box below)	Please see attached.
Attachments	📎 Trendlines January 2016 Update.pdf Total size =100K

Like 0 Tweet G+1 0

Trendlines January 2016 Update

Misgav, Israel – 1 February 2016 – The Trendlines Group Ltd. (“Trendlines”) is pleased to provide this update about its recent activities and developments related to its portfolio companies.

Trendlines Agtech Establishes and Invests in AquiNovo

AquiNovo Ltd. (“AquiNovo”) was established in our Trendlines Agtech – Mofet Ltd. (“Trendlines Agtech”) facilities. We invested in the company, and it has received substantial additional funding from the Israeli government. AquiNovo is developing proprietary materials to block reproductive hormone receptors in fish to inhibit puberty for enhanced growth.

6th Annual Trendlines Company Showcase

On 27 January 2016 we held our [6th Annual Company Showcase](#), the largest ever, with more than 400 attendees.

Gerald Ong, Chief Executive Officer of Singapore’s PrimePartners Corporate Finance Pte. Ltd., addressed the Singapore opportunity in his keynote address, and Prof. Dr. Hanns-Peter Knaebel of B. Braun’s Aesculap Division, spoke about the balancing act companies face when working with multinationals. A special afternoon session featured a panel discussion with members of the Singapore business, financial, and legal communities, including Nasser Ismail of the Singapore Exchange.

The heart of the Showcase was presentations by 10 of our portfolio companies. The Showcase gave the companies an opportunity to present to a wide audience of investors, industry players and government leaders. This year’s attendees included delegations from Singapore, China, and the United States.

News from Our Portfolio Companies

Successful Results for EdenShield

[EdenShield](#) Ltd. (“EdenShield”) announced successful field trial results of its GateKeeper system on greenhouse tomatoes in Italy. The independent study, conducted by a contract research organization, demonstrated that the GateKeeper system kept almost 100% of crop-destroying pests out of greenhouses — while reducing pesticide consumption by 80%. EdenShield's news was featured in an article in the *Times of Israel*.

ApiFix TV Interview

[ApiFix](#) Ltd. (“ApiFix”) Founder and Head of the Israeli Center for Spine Surgery Prof. Yizhar Floman was interviewed by Natasha Raquel Kurtchuk on Israel Daily (ILTV) about how the company’s unique device presents a breakthrough treatment for adolescent idiopathic scoliosis. ApiFix has received CE clearance for sale of its device in Europe and has performed 65 successful surgeries in Europe and Israel.

NeuroQuest Featured in Israel21c

[NeuroQuest](#) Ltd. ("**NeuroQuest**") made the news with its announcement that it will be starting a 700-patient U.S. clinical trial of its simple blood test to diagnose Alzheimer's in older individuals at risk.

Human trials in Israel demonstrated NeuroQuest's blood test to be 87% accurate, with an 85% specificity rate in detecting the presence of beta amyloid, the development of which is associated with Alzheimer's. With blood tests, results over 70% are considered medically significant.

Validation studies for the company's diagnostic blood test will continue in Australia and in the United States through 2017.

Trendlines Medical CEO Eran Feldhay Attends J.P. Morgan Conference

Eran Feldhay, Chief Executive Officer of Trendlines Medical – Misgav ("**Trendlines Medical**"), attended the J.P. Morgan 34th Annual Healthcare Conference in San Francisco, from 11 to 14 January 2016. "It was a great opportunity to gain exposure for our incubator and our portfolio companies, as well as learning about new trends in the global healthcare field," remarked Eran.

ViAqua Appears in the News

Shai Einbinder and Shay Ufaz, co-founders of [ViAqua](#) Therapeutics Ltd. ("**ViAqua**"), explained the idea behind their company to the Israeli media: "Just like children who get every disease when they start kindergarten, shrimp respond with multiple diseases when they make the transition from the open sea to crowded fisheries. This is a very big problem for humanity, considering that shrimp feed billions of people and are one of the major sources of protein. Shrimp cannot protect themselves against new diseases, so a country like the Philippines remains powerless in its attempts to supply the consumers. ViAqua adapted technology developed for humans and has developed a vaccine that will protect shrimp against viruses."

- End -

The Trendlines Group Ltd. (the "Company") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 26 November 2015. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor").

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGXST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.